COVID-19 Biological Samples Collection (COLCOV19-BX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04332016|
Recruitment Status : Recruiting
First Posted : April 2, 2020
Last Update Posted : April 3, 2020
The coronavirus disease 2019 (COVID-19) outbreak is now considered as a public health emergency of international concern by the World Health Organization.
In the context of the health emergency, research on the pathogen (the SARS-CoV-2 coronavirus), the disease and the therapeutic care is being organized. Research projects require the use of biological samples. This study aims at setting up a collection of biological samples intended for application projects in any discipline.
The main objective of the study is to collect, process and store biological samples from patients and caregivers infected with SARS-CoV-2 (COVID-19) at the biological ressources center of the Bordeaux University Hospital.
|Condition or disease||Intervention/treatment|
|Infection Viral||Other: biological samples collection|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Biological Samples Collection From Patients and Caregivers Treated at Bordeaux University Hospital for Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Infection (COVID-19).|
|Actual Study Start Date :||April 2, 2020|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||March 2023|
|COVID-19 infected patients||
Other: biological samples collection
collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
- COVID-19 desease description [ Time Frame: Inclusion visit (Day 1) ]
From blood samples: protein levels, whole genome sequence, transcriptomic analysis data.
From upper respiratory samples: protein levels, virus transcriptomic analysis data.
From stool: microbiota analysis data.
From urine: protein level.
- COVID-19 desease description [ Time Frame: Day 30 to 90 ]From blood samples: protein levels.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04332016
|Contact: Isabelle PELLEGRIN||05 57 82 11 email@example.com|
|Contact: Aurélie POUZET||05 57 82 17 firstname.lastname@example.org|